RFK Jr. and other Trump officials embrace psychedelics after FDA setback

Psychedelic drugs are gaining political momentum as Health Secretary Robert F. Kennedy Jr. and other Trump officials signal interest in approving psychedelics for hard-to-treat mental health conditions after an FDA setback. The push includes proposals that could speed reviews and reduce reliance on placebo controlled trials, while some experts warn that hype could outrun the evidence and jeopardize patients if clinical benchmarks are bypassed. Meanwhile, Texas is funding a major ibogaine study for opioid addiction, PTSD, and other conditions, even though ibogaine remains a Schedule 1 drug. The article also highlights concerns about ibogaine risks such as potentially dangerous heart rhythm effects and contrasts state level initiatives with earlier federal research that was discontinued due to cardiovascular toxicity.